Get the Stockscreener App
10.09
1.10%
0.11
After Hours:
10.09
Kalvista Pharmaceuticals Inc stock is traded at $10.09, with a volume of 160.25K.
It is up +1.10% in the last 24 hours and down -13.61% over the past month.
See More
Previous Close:
$9.98
Open:
$10.08
24h Volume:
160.25K
Relative Volume:
0.40
Market Cap:
$453.33M
Revenue:
-
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.193
EPS:
-3.16
Net Cash Flow:
$-97.15M
1W Performance:
+12.61%
1M Performance:
-13.61%
6M Performance:
-10.71%
1Y Performance:
+24.88%
1-Day Range:
$9.95
$10.27
1-Week Range:
$8.75
$10.48
52-Week Range:
$7.39
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
10.09 | 453.33M | 0 | -108.30M | -97.15M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals' chief medical officer sells $21,586 in stock - Investing.com
KalVista Pharmaceuticals' chief development officer sells $19,378 in stock By Investing.com - Investing.com Australia
Insiders At KalVista Pharmaceuticals Sold US$2.5m Of Stock Potentially Indicating Weakness - Simply Wall St
KalVista appoints biotech veteran to board By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors - citybiz
KalVista appoints biotech veteran to board - Investing.com
KalVista Pharmaceuticals Appoints Laurence Reid to Board - TipRanks
KalVista Strengthens Board with Biotech Veteran Dr. Laurence Reid as Director | KALV Stock News - StockTitan
KalVista: Upcoming PDUFA, But Not Without Risks (NASDAQ:KALV) - Seeking Alpha
Hereditary Angioedema Market Expected to Experience Major - openPR
Objective long/short (KALV) Report - Stock Traders Daily
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals CMO sells shares worth $74,765 By Investing.com - Investing.com Canada
Kalvista Pharmaceuticals CMO sells shares worth $74,765 - Investing.com India
Paul K. Audhya Sells 8,077 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $133,344.00 in Stock - MarketBeat
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 - Investing.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by First Turn Management LLC - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Suvretta Capital Management, LLC Increases Stake in KalVista Pha - GuruFocus.com
Insight into TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of KalVista Pharmaceuticals Inc Shares - GuruFocus.com
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuti - GuruFocus.com
Capital World Investors Expands Stake in KalVista Pharmaceuticals - GuruFocus.com
KalVista Pharma (KALV) to Present at Stifel and Jefferies Healthcare Conferences | KALV Stock News - StockTitan
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian
Leerink Partnrs Has Bullish Estimate for KALV Q3 Earnings - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance
KalVista prices $55M stock offering - MSN
Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com
KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com
U.S. Dollar/Moldova Lei (USDMDL) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap UpHere's Why - MarketBeat
KalVista sets pricing for $60 million stock offering - Investing.com
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart
Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Business Wire
KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com
Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
(KALV) Long Term Investment Analysis - Stock Traders Daily
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa
sebetralstat shows promise in phase 3 HAE trial - Investing.com India
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):